Topical Timolol (Timoptic) for rosacea lesions around the eye

Written by on December 1, 2010 in clinical trials, Ocular Rosacea with 0 Comments

A new clinical trial is proposing to look at using a non-cardioselective beta-blocker, Timolol Opthalmic, to treat ocular rosacea based benign vascular lesions on the eyelid. The condition is chronic as it can lead to blindness.

Timolol has been used orally in the treatment for hypertension and opthalmic solutions have been used to reduce intraocular pressure in glaucoma.

Clinical Trial NCT01250457: Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

Pre-treatment and post-treatment lesion size will then be compared to determine whether twice-daily topical application of timolol 0.5% solution alters the morphometry of benign vascular periocular lesions.

Benign vascular tumors of the eyelid are common causes of ocular morbidity. Capillary hemangiomas in children cause refractive and occlusive amblyopia. In adults, Rosacea-associated eyelid telangiectasis and sclerosis can result in keratitis and corneal neovascularization.

Corticosteroid therapy of benign vascular lesions risks sight-threatening complications including central retinal artery occlusion and significant systemic morbidity.

Alternatively, oral and intravenous beta-blockers have been reported to induce regression of benign vascular lesions. One recent report documented efficacy of topical timolol in treating a large capillary hemangioma of the eyelid in a child.

Topical application reduces systemic side effects of beta-blockers including bradycardia, hypotension, heart block, and bronchospasm. This one-year prospective case-control series will investigate whether topical Timolol 0.5% solution applied twice daily causes significant regression of benign vascular periocular lesions.

Related Articles

Read more about: clinical trials, Ocular Rosacea

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.